Streetbeat News

Analyst Ratings

CSR

RBC Capital analyst Brad Heffern has maintained a 'Sector Perform' rating on Centerspace (NYSE:CSR) but lowered the price target from $60 to $58.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:21 pm

AEIS

Susquehanna analyst Mehdi Hosseini has maintained a Neutral rating on Advanced Energy Indus (NASDAQ:AEIS) and lowered the price target from $110 to $95.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:17 pm

TECH

RBC Capital analyst Conor McNamara has maintained a 'Sector Perform' rating on Bio-Techne (NASDAQ:TECH) and lowered the price target from $85 to $83.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:16 pm

ACGL

RBC Capital analyst Scott Heleniak maintains an Outperform rating on Arch Capital Group (NASDAQ:ACGL) and raises the price target from $90 to $98.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:13 pm

XPOF

Bank of America Securities has downgraded Xponential Fitness from 'Buy' to 'Neutral' and reduced its price target from $35 to $16. This has led to a decrease in the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:13 pm

APLS

Needham analyst Joseph Stringer maintains a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $60 to $63.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:11 pm

AMGN

RBC Capital analyst Gregory Renza has maintained a 'Sector Perform' rating on Amgen (NASDAQ:AMGN) and raised the price target from $253 to $256.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:10 pm

W

Needham analyst Anna Andreeva has maintained a 'Buy' rating on Wayfair (NYSE:W) but lowered the price target from $100 to $75.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:06 pm

DXCM

A significant bullish stance has been taken on DexCom (NASDAQ:DXCM) by a large investor, as observed in the unusual options activity. The sentiment among these big-money traders is split between 58% bullish and 41% bearish. The whales have been targeting a price range from $90.0 to $100.0 for DexCom over the last 3 months. The price of DXCM is currently down -0.03% at $88.8. Analysts from JP Morgan, Stifel, Leerink Partners, and Morgan Stanley have maintained their ratings on DexCom with price targets ranging from $100 to $145.

Portfolio Pulse from Benzinga Insights

November 01, 2023 | 4:02 pm

ADUS

RBC Capital analyst Ben Hendrix has maintained an 'Outperform' rating on Addus HomeCare (NASDAQ:ADUS), but lowered the price target from $109 to $102.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 4:01 pm